Last updated on April 16, 2014 at 17:34 EDT

Lupin Launches Generic ZYMAXID(TM) Ophthalmic Solution in the US

October 3, 2013

MUMBAI, India and BALTIMORE, October 3, 2013 /PRNewswire/ –

Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin
Pharmaceuticals, Inc. (LPI), has launched its generic Gatifloxacin Ophthalmic Solution,
0.5%. Lupin had earlier received final approval from the United States Food and Drugs
Administration (US FDA) to market a generic version of Allergan Inc.’s Zymaxid(TM)
Ophthalmic Solution, 0.5%.

Lupin’s Gatifloxacin Ophthalmic solution 0.5% is the generic equivalent of Zymaxid(TM)
Ophthalmic Solution of Allergan and is indicated for the treatment of bacterial
conjunctivitis. Zymaxid(TM) Ophthalmic Solution, 0.5%, had annual U.S sales of
approximately US$ 62.3 million (IMS MAT Jun 2013). Lupin was the first applicant to file
an ANDA for Zymaxid(TM) Ophthalmic Solution and as such will be entitled to 180 days of
marketing exclusivity.

Commenting on the approval, Nilesh Gupta, Managing Director, Lupin Limited, said,
“Having received approval earlier, we are happy to now launch this product. The product is
the first of the ophthalmic products that Lupin is bringing to the market and bears
testimony to our continued commitment to serving our customers and patients by bringing
high quality, affordable medicines.”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company producing and
developing a wide range of branded and generic formulations and APIs globally. The Company
is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI,
Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and
Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3%
market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical
company by sales. The Company is also the fastest growing top 10 generic pharmaceutical
players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin’s Consolidated turnover and Profit
after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242
million) respectively. Please visit http://www.lupinworld.com for more information.

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to
delivering high-quality, affordable generic medicines and branded formulations trusted by
healthcare professionals and patients across geographies. For more information, visit


Safe Harbor Statement [http://www.lupinworld.com/safe harbor ]

* Zymaxid(TM) is the registered trademark of Allergan Inc.

For more information, please contact -

        Shamsher Gorawara
        Head - Corporate Communications
        Ph: +91-98-20-338-555
        Email: shamshergorawara@lupinworld.com

SOURCE Lupin Ltd

Source: PR Newswire